For Doctors in a Hurry
- Researchers evaluated if the high-sensitivity cardiac troponin T generation 6 assay improves diagnostic performance compared to the current generation 5 version.
- This prospective diagnostic study analyzed 3,346 emergency department patients with suspected myocardial infarction to compare the two troponin assays.
- The generation 6 assay showed comparable diagnostic accuracy (AUC 0.927) while identifying significantly fewer patients with myocardial injury (35.9% versus 43.5%).
- The researchers concluded that the generation 6 assay provides high sensitivity and specificity using optimized 0/1-hour and 0/2-hour algorithms.
- Clinicians may use these assay-specific cutoffs to safely rule out myocardial infarction in over half of presenting patients.
Refining the Triage of Suspected Myocardial Infarction
Rapidly triaging patients with suspected non-ST-segment elevation myocardial infarction is a central challenge in emergency medicine. Current practice relies on high-sensitivity cardiac troponin (hs-cTn) assays and accelerated diagnostic pathways, such as the European Society of Cardiology 0/1-hour algorithm, to safely rule in or rule out events based on troponin levels and their early change [1, 2, 3]. While these protocols are effective, a frequent clinical dilemma is the detection of elevated troponin that signifies myocardial injury from non-ischemic causes rather than an acute infarction, potentially leading to unnecessary downstream testing [4, 5]. A recent secondary analysis of a large, prospective study has now evaluated the clinical performance of a next-generation hs-cTnT assay, specifically examining its accuracy and its utility within these established rapid triage frameworks.
Comparative Accuracy and Patient Characteristics
To assess the new assay's clinical utility, researchers performed a secondary analysis of the Advantageous Predictors of Acute Coronary Syndromes Evaluation (APACE) study, an international, prospective trial (NCT00470587). The study enrolled 3,346 patients presenting to the emergency department with symptoms suggestive of myocardial infarction. Diagnoses were confirmed through central adjudication, a process where an independent committee of experts reviews each case to ensure a consistent and rigorous diagnostic standard. Within this cohort, myocardial infarction was the final diagnosis in 616 patients (18.4%). For each participant, both the new high-sensitivity cardiac troponin T-generation 6 (hs-cTnT-gen6) and the current hs-cTnT-generation 5 (hs-cTnT-gen5) assays were measured at identical time points to allow for a direct comparison.
The study first established that the higher analytical sensitivity of the new assay, which is its ability to detect very low concentrations of the protein, did not alter its overall diagnostic performance. The diagnostic accuracy at presentation, measured by the area under the curve (a statistical metric where 1.0 indicates a perfect test), was 0.927 (95% CI: 0.918-0.937) for the hs-cTnT-gen6 assay. This was statistically comparable to the 0.931 (95% CI: 0.921-0.94) observed for the established hs-cTnT-gen5 assay. These results confirm that the newer assay reliably differentiates patients with and without myocardial infarction upon initial evaluation.
Reduction in Non-Ischemic Myocardial Injury
A key finding emerged not in overall diagnostic accuracy, but in the new assay's improved ability to distinguish acute events from background myocardial injury. Myocardial injury is defined as any troponin concentration above the 99th percentile upper reference limit. Using this threshold, the hs-cTnT-gen6 assay identified myocardial injury in 35.9% of patients, a significant reduction from the 43.5% flagged by the hs-cTnT-gen5 assay (P < 0.001). This reduction is clinically meaningful, as it may help clinicians better differentiate acute coronary events from the many other conditions, such as sepsis or chronic kidney disease, that can cause minor, non-ischemic troponin elevations.
For the practicing physician, this improved specificity suggests the hs-cTnT-gen6 assay may decrease the frequency of ambiguous positive results that trigger extensive workups. By more effectively filtering out minor, non-specific troponin elevations while maintaining high sensitivity for true infarctions, the assay could help focus resources on patients with the highest likelihood of an acute coronary syndrome. The findings were consistent in sensitivity analyses and in an external validation cohort, indicating the robustness of this observation.
Beyond its general performance, the study established and validated specific cutoffs for the hs-cTnT-gen6 assay within the European Society of Cardiology's accelerated 0/1-hour and 0/2-hour diagnostic pathways. For immediate rule-out at presentation, a baseline hs-cTnT-gen6 concentration of <6 ng/L excluded non-ST-segment elevation myocardial infarction in 30.0% of patients with 100% sensitivity (95% CI: 99.4%-100%). This high negative predictive value was maintained irrespective of the time from chest pain onset, providing a reliable tool for rapidly identifying very low-risk patients.
Applying the 0/1-hour algorithm, which incorporates both a baseline value and the absolute change (delta) over one hour, demonstrated high efficiency. A rule-out strategy using an hs-cTnT-gen6 cutoff of <8 ng/L at presentation (if chest pain onset >3 hours) or <18 ng/L with a 1-hour delta of <2 ng/L safely excluded myocardial infarction in 56.3% of the cohort. This was achieved with a sensitivity of 99.7% (95% CI: 98.3%-99.9%). For ruling in a diagnosis, a baseline concentration ≥112 ng/L or a 1-hour delta ≥10 ng/L identified 20.0% of patients as having myocardial infarction with a specificity of 93.4% (95% CI: 92.0%-94.6%).
The 0/2-hour algorithm yielded similarly robust results. A rule-out strategy using a baseline hs-cTnT-gen6 concentration <8 ng/L (if chest pain onset >3 hours) or <18 ng/L with a 2-hour delta <4 ng/L excluded myocardial infarction in 51.1% of patients with a sensitivity of 99.7% (95% CI: 98.1%-99.9%). The corresponding rule-in criteria, a baseline concentration ≥112 ng/L or a 2-hour delta ≥15 ng/L, identified 23.9% of patients with a specificity of 92.7% (95% CI: 90.8%-94.2%). These validated, assay-specific cutoffs provide a rigorous framework for the safe and efficient triage of patients with suspected myocardial infarction in the emergency department.
References
1. Collet J, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal. 2020. doi:10.1093/eurheartj/ehaa575
2. Nomura O, Hashiba K, Kikuchi M, et al. Performance of the 0-Hour/1-Hour Algorithm for Diagnosing Myocardial Infarction in Patients With Chest Pain in the Emergency Department - A Systematic Review and Meta-Analysis.. Circulation reports. 2022. doi:10.1253/circrep.CR-22-0001
3. Al-Saleh A, Alazzoni A, Shalash SA, et al. Performance of the high-sensitivity troponin assay in diagnosing acute myocardial infarction: systematic review and meta-analysis.. CMAJ open. 2014. doi:10.9778/cmajo.20130074
4. Burgos LM, Trivi M, Costabel JP. Performance of the European Society of Cardiology 0/1-hour algorithm in the diagnosis of myocardial infarction with high-sensitivity cardiac troponin: Systematic review and meta-analysis.. European heart journal. Acute cardiovascular care. 2021. doi:10.1177/2048872620935399
5. Arslan M, Dedic A, Boersma E, Dubois EA. Serial high-sensitivity cardiac troponin T measurements to rule out acute myocardial infarction and a single high baseline measurement for swift rule-in: A systematic review and meta-analysis.. European heart journal. Acute cardiovascular care. 2020. doi:10.1177/2048872618819421
